483 related articles for article (PubMed ID: 30757913)
21. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
Nawar AE; Wasfy T; Shafik HM
BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema.
Bolukbasi S; Cakir A; Erden B; Karaca G
Cutan Ocul Toxicol; 2019 Dec; 38(4):401-405. PubMed ID: 31438736
[No Abstract] [Full Text] [Related]
23. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Arnold JJ; Mehta H; Duran MA; Bougamha W; Carreño E; Viola F; Squirrell D; Barthelmes D; Gillies M
Retina; 2022 Jun; 42(6):1085-1094. PubMed ID: 35174799
[TBL] [Abstract][Full Text] [Related]
24. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
25. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
[TBL] [Abstract][Full Text] [Related]
26. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
Yucel OE; Birinci H; Sullu Y
Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
29. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
[TBL] [Abstract][Full Text] [Related]
30. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
31. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
[TBL] [Abstract][Full Text] [Related]
32. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion.
Spooner K; Fraser-Bell S; Hong T; Chang A
Asia Pac J Ophthalmol (Phila); 2020; 9(1):48-53. PubMed ID: 31990746
[TBL] [Abstract][Full Text] [Related]
33. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
34. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
[TBL] [Abstract][Full Text] [Related]
35. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
Wood EH; Karth PA; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
[TBL] [Abstract][Full Text] [Related]
36. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
[TBL] [Abstract][Full Text] [Related]
37. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
38. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
39. Initial utilization of aflibercept in exudative age-related macular degeneration.
Cho H; Weber ML; Shah CP; Heier JS
Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
